{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:34:14Z","timestamp":1793712854472,"version":"4.6.1"},"reference-count":178,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013947","name":"Modern Humanities Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000848","name":"The University of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.molmed.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:25:18Z","timestamp":1674447918000},"page":"255-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-3554","authenticated-orcid":false,"given":"Rupsha","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Orta-Resendiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mazein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Dockrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2023.01.003_bb0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2023.01.003_bb0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","article-title":"Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children","volume":"40","author":"Loske","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210583","article-title":"Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics","volume":"218","author":"Cheemarla","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0020","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1038\/ncomms10224","article-title":"RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection","volume":"6","author":"Jozwik","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.003_bb0040","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0050","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.molmed.2023.01.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2143283","article-title":"Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice","volume":"12","author":"Liu","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.molmed.2023.01.003_bb0070","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMc2212772","article-title":"Neutralization of omicron subvariant BA.2.75 after bivalent vaccination","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0075","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0080","series-title":"ETF concludes that bivalent original\/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.molmed.2023.01.003_bb0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molmed.2023.01.003_bb0090","doi-asserted-by":"crossref","first-page":"ofac135","DOI":"10.1093\/ofid\/ofac135","article-title":"Viral load among vaccinated and unvaccinated, asymptomatic and symptomatic persons infected with the SARS-CoV-2 delta variant","volume":"9","author":"Acharya","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.molmed.2023.01.003_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1473-3099(21)00768-4","article-title":"Transmissibility of SARS-CoV-2 among fully vaccinated individuals","volume":"22","author":"Franco-Paredes","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molmed.2023.01.003_bb0100","series-title":"Stop calling it a pandemic of the unvaccinated. The Atlantic 21 September","author":"Tarag","year":"2021"},{"key":"10.1016\/j.molmed.2023.01.003_bb0105","doi-asserted-by":"crossref","first-page":"15729","DOI":"10.1038\/s41598-021-95025-3","article-title":"Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains","volume":"11","author":"Rella","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002198","article-title":"Imperfect vaccination can enhance the transmission of highly virulent pathogens","volume":"13","author":"Read","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.003_bb0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(21)00468-2","article-title":"Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection","volume":"397","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.003_bb0130","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.003_bb0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0140","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0145","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ajpath.2021.10.019","article-title":"Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas","volume":"192","author":"Christensen","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0155","article-title":"Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections","author":"Venkatakrishnan","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.molmed.2023.01.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010876","article-title":"Shedding of infectious SARS-CoV-2 despite vaccination","volume":"18","author":"Riemersma","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2023.01.003_bb0165","doi-asserted-by":"crossref","first-page":"612.e1","DOI":"10.1016\/j.cmi.2021.11.010","article-title":"Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study","volume":"28","author":"Chia","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.molmed.2023.01.003_bb0170","article-title":"Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies","author":"Noori","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0175","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0180","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0185","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0190","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients","volume":"75","author":"Lu","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2023.01.003_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0200","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice","volume":"29","author":"Scheaffer","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0210","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13690-022-00935-x","article-title":"Duration of immunity following full vaccination against SARS-CoV-2: a systematic review","volume":"80","author":"Addo","year":"2022","journal-title":"Arch. Public Health"},{"key":"10.1016\/j.molmed.2023.01.003_bb0215","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0220","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.003_bb0225","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0230","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.15585\/mmwr.mm7037a7","article-title":"New COVID-19 cases and hospitalizations among adults, by vaccination status - New York, May 3-July 25, 2021","volume":"70","author":"Rosenberg","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.molmed.2023.01.003_bb0235","series-title":"Mid-term effectiveness of BNT162b2 and ChAdOx1 vaccines in users of the ZOE COVID Symptom Study app in the UK","author":"ZOE COVID Study","year":"2021"},{"key":"10.1016\/j.molmed.2023.01.003_bb0240","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","article-title":"Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors","volume":"13","author":"P\u00e9rez-Al\u00f3s","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0245","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molmed.2023.01.003_bb0250","article-title":"Waning of vaccine effectiveness against moderate and severe Covid-19 among adults in the US from the VISION network: test negative, case-control study","volume":"379","author":"Ferdinands","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2023.01.003_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0260","article-title":"Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers","volume":"2","author":"Nakayama","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1189\/jlb.0313180","article-title":"Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection","volume":"95","author":"Wu","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0275","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0280","author":"World Health Organization"},{"key":"10.1016\/j.molmed.2023.01.003_bb0285","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.chom.2022.04.017","article-title":"SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies","volume":"30","author":"Arora","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0290","article-title":"Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD","volume":"3","author":"Li","year":"2022","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.molmed.2023.01.003_bb0295","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq1841","article-title":"Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure","author":"Reynolds","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.12688\/f1000research.52341.2","article-title":"Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics","volume":"10","author":"Rochman","year":"2021","journal-title":"F1000Res."},{"key":"10.1016\/j.molmed.2023.01.003_bb0305","doi-asserted-by":"crossref","unstructured":"P. Kearns, et al. (2021). Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity \u2013 the OCTAVE Trial. Published online August 23, 2021. http:\/\/dx.doi.org\/10.2139\/ssrn.3910058.","DOI":"10.2139\/ssrn.3910058"},{"key":"10.1016\/j.molmed.2023.01.003_bb0310","article-title":"Covid-19: 40% of patients with weakened immune system mount lower response to vaccines","volume":"374","author":"Munro","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2023.01.003_bb0315","doi-asserted-by":"crossref","first-page":"eabj1031","DOI":"10.1126\/sciimmunol.abj1031","article-title":"Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients","volume":"6","author":"Rincon-Arevalo","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2023.01.003_bb0325","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jmv.27485","article-title":"Host factors and vaccine efficacy: Implications for COVID-19 vaccines","volume":"94","author":"Falahi","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0330","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2666-7568(21)00168-9","article-title":"Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study","volume":"2","author":"Tut","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.molmed.2023.01.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100928","article-title":"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine","volume":"36","author":"Pellini","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.molmed.2023.01.003_bb0340","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/d41586-020-02946-6","article-title":"How obesity could create problems for a COVID vaccine","volume":"586","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0345","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained - a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0350","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection","volume":"387","author":"Havervall","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039194","article-title":"Tissue resident memory T cells \u2014 a new benchmark for the induction of vaccine-induced mucosal immunity","volume":"13","author":"Hassert","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0360","doi-asserted-by":"crossref","first-page":"eabd8003","DOI":"10.1126\/sciimmunol.abd8003","article-title":"Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells","volume":"6","author":"Rakhra","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0365","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01686-16","article-title":"Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis","volume":"7","author":"Perdomo","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.molmed.2023.01.003_bb0370","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1038\/s41467-021-23333-3","article-title":"Peripheral and lung resident memory T cell responses against SARS-CoV-2","volume":"12","author":"Grau-Exp\u00f3sito","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249499","article-title":"Human IgG and IgA responses to COVID-19 mRNA vaccines","volume":"16","author":"Wisnewski","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2023.01.003_bb0380","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam6970","article-title":"Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection","volume":"2","author":"Pizzolla","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0385","article-title":"Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses","volume":"3","author":"Ishii","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0390","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.immuni.2021.03.005","article-title":"Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19","volume":"54","author":"Szabo","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2023.01.003_bb0395","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0400","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.immuni.2013.09.013","article-title":"Lung airway-surveilling CXCR3hi memory CD8+ T cells are critical for protection against influenza A virus","volume":"39","author":"Sl\u00fctter","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2023.01.003_bb0405","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cell.2020.04.042","article-title":"Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection","volume":"181","author":"Netea","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0410","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2018.09.042","article-title":"Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity","volume":"175","author":"Yao","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0415","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41590-019-0583-y","article-title":"Training the trainable cells of the immune system and beyond","volume":"21","author":"Kar","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0420","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101718118","article-title":"Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics","volume":"118","author":"Chumakov","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.003_bb0425","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2023.01.003_bb0430","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mi.2013.67","article-title":"Lung niches for the generation and maintenance of tissue-resident memory T cells","volume":"7","author":"Turner","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0435","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3389\/fimmu.2019.02075","article-title":"Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T cells","volume":"10","author":"Haddadi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0440","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2023.01.003_bb0450","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2018.01.006","article-title":"New tuberculosis vaccine strategies: taking aim at un-natural immunity","volume":"39","author":"Jeyanathan","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2023.01.003_bb0460","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0465","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","article-title":"Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2","volume":"185","author":"Afkhami","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0470","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0475","doi-asserted-by":"crossref","first-page":"e00114","DOI":"10.1128\/JVI.00114-18","article-title":"Activation and induction of antigen-specific T follicular helper cells play a critical role in live-attenuated influenza vaccine-induced human mucosal anti-influenza antibody response","volume":"92","author":"Aljurayyan","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0480","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13578-021-00723-0","article-title":"Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2","volume":"11","author":"Cao","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.molmed.2023.01.003_bb0485","doi-asserted-by":"crossref","first-page":"eabn1413","DOI":"10.1126\/scitranslmed.abn1413","article-title":"Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity","volume":"14","author":"Hartwell","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0490","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0495","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","article-title":"Mucosal vaccines: strategies and challenges","volume":"217","author":"Li","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.molmed.2023.01.003_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: from bench to bed","volume":"76","author":"Alu","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.molmed.2023.01.003_bb0505","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2023.01.003_bb0510","article-title":"The BioNTech \/ Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization","author":"Lixenfeld","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.molmed.2023.01.003_bb0515","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744887","article-title":"The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines","volume":"12","author":"Chan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0525","first-page":"693","article-title":"Cross-reactive tissue-resident CD8+ T cells may provide first line of defence against SARS-CoV-2","volume":"21","author":"Flemming","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0530","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/imm.12929","article-title":"The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination","volume":"154","author":"Gray","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.molmed.2023.01.003_bb0535","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/s41467-022-30913-4","article-title":"Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination","volume":"13","author":"Ssemaganda","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0540","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41385-018-0003-x","article-title":"Pulmonary antigen encounter regulates the establishment of tissue-resident CD8 memory T cells in the lung airways and parenchyma","volume":"11","author":"McMaster","year":"2018","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0545","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0550","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abl8912","article-title":"Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates","volume":"374","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0555","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1751-7915.2011.00284.x","article-title":"Nanoparticles for transcutaneous vaccination","volume":"5","author":"Hansen","year":"2012","journal-title":"Microb. Biotechnol"},{"key":"10.1016\/j.molmed.2023.01.003_bb0560","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7774\/cevr.2014.3.1.42","article-title":"Microneedle patches for vaccine delivery","volume":"3","author":"Suh","year":"2014","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.molmed.2023.01.003_bb0565","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","article-title":"Induction of mucosal immunity through systemic immunization: phantom or reality?","volume":"12","author":"Su","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.molmed.2023.01.003_bb0570","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/vaccines9121499","article-title":"Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID-19 vaccine compared to SARS-CoV-2 natural infection","volume":"9","author":"Guerrieri","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.molmed.2023.01.003_bb0575","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1073\/pnas.1202288109","article-title":"Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation","volume":"109","author":"Mackay","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.003_bb0580","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0194599820982633","article-title":"COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission","volume":"164","author":"Bleier","year":"2021","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.molmed.2023.01.003_bb0585","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220780","article-title":"SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity","volume":"219","author":"Lim","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0590","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0595","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/158128","article-title":"The early activation of CD8+ T cells is dependent on type I IFN signaling following intramuscular vaccination of adenovirus vector","volume":"2014","author":"Hemmi","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.molmed.2023.01.003_bb0600","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.it.2021.02.003","article-title":"Dual nature of type I interferons in SARS-CoV-2-induced inflammation","volume":"42","author":"King","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1084\/jem.20150712","article-title":"Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide","volume":"213","author":"Madera","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0610","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.4049\/jimmunol.178.6.3505","article-title":"Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus","volume":"178","author":"Zhu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0615","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2019.01.013","article-title":"The role of type I interferons in CD4+ T cell differentiation","volume":"215","author":"Kuka","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.molmed.2023.01.003_bb0620","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2018.00614","article-title":"Induction of type I interferons by therapeutic nanoparticle-based vaccination is indispensable to reinforce cytotoxic CD8+ T cell responses during chronic retroviral infection","volume":"9","author":"Knuschke","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0625","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/v12121433","article-title":"Dysregulated interferon response underlying severe COVID-19","volume":"12","author":"Lopez","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.molmed.2023.01.003_bb0630","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0635","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0640","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.3390\/ijms21176351","article-title":"Natural killer cell dysfunction and its role in COVID-19","volume":"21","author":"van Eeden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2023.01.003_bb0645","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2009.07.005","article-title":"Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells","volume":"31","author":"Cucak","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2023.01.003_bb0650","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.4049\/jimmunol.176.7.4343","article-title":"Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection","volume":"176","author":"Coro","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0655","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1084\/jem.20092695","article-title":"Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response","volume":"207","author":"Swanson","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0660","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","article-title":"Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN","volume":"176","author":"Le Bon","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0665","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/s41467-021-26861-0","article-title":"Epromoters function as a hub to recruit key transcription factors required for the inflammatory response","volume":"12","author":"Santiago-Algarra","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.003_bb0670","doi-asserted-by":"crossref","first-page":"E9162","DOI":"10.1073\/pnas.1720930115","article-title":"Interferon stimulation creates chromatin marks and establishes transcriptional memory","volume":"115","author":"Kamada","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.003_bb0675","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0680","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Trouillet-Assant","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0685","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.003_bb0690","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2666-5247(21)00027-6","article-title":"Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics","volume":"2","author":"Schroeder","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010272","article-title":"Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection","volume":"18","author":"Varese","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2023.01.003_bb0700","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","article-title":"The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection","volume":"14","author":"Gallo","year":"2021","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0705","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41577-020-00470-2","article-title":"Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19","volume":"21","author":"Alon","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0710","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1465-9921-10-97","article-title":"Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung","volume":"10","author":"Kawamata","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.molmed.2023.01.003_bb0715","series-title":"Lymphocyte Trafficking in Health and Disease","first-page":"115","article-title":"Lymphocyte trafficking and chemokine receptors during pulmonary disease","author":"Lukacs","year":"2006"},{"key":"10.1016\/j.molmed.2023.01.003_bb0720","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3389\/fimmu.2019.01650","article-title":"Site-specific DC surface signatures influence CD4+ T cell co-stimulation and lung-homing","volume":"10","author":"Pejoski","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0725","doi-asserted-by":"crossref","first-page":"11369","DOI":"10.1038\/s41598-022-15238-y","article-title":"Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine","volume":"12","author":"Lin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.003_bb0730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41421-022-00411-4","article-title":"Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2","volume":"8","author":"Lin","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.molmed.2023.01.003_bb0735","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1515\/BC.2008.051","article-title":"Adjuvant activity of type I interferons","volume":"389","author":"Tovey","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.molmed.2023.01.003_bb0740","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/107999099314298","article-title":"Oromucosal interferon therapy: marked antiviral and antitumor activity","volume":"19","author":"Tovey","year":"1999","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.molmed.2023.01.003_bb0745","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/cncr.22253","article-title":"Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-\u03b1-2b in patients with metastatic renal cell carcinoma","volume":"107","author":"Tannir","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2023.01.003_bb0750","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdm180","volume":"18","author":"Sirohi","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0755","article-title":"Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo","volume":"3","author":"Gary","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0760","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41385-018-0124-2","article-title":"Zymosan by-passes the requirement for pulmonary antigen encounter in lung tissue-resident memory CD8+ T cell development","volume":"12","author":"Caminschi","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0765","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.molmed.2023.01.003_bb0770","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12950-020-00249-1","article-title":"Efficacy and safety of aerosol inhalation of recombinant human interferon \u03b11b (IFN\u03b11b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"17","author":"Jiang","year":"2020","journal-title":"J. Inflamm. (Lond.)"},{"key":"10.1016\/j.molmed.2023.01.003_bb0775","doi-asserted-by":"crossref","first-page":"2229735","DOI":"10.1155\/2022\/2229735","article-title":"Safety and effectiveness of inhaling different dosage recombinant human interferon \u03b11B for bronchiolitis in children: a systematic review and meta-analysis","volume":"2022","author":"Luo","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0780","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b192b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0785","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","article-title":"Functional classification of interferon-stimulated genes identified using microarrays","volume":"69","author":"de Veer","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0790","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"Le Bon","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0795","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0800","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.ai.2018.02.002","article-title":"Chemokines: critical regulators of memory T cell development, maintenance, and function","volume":"138","author":"Rahimi","year":"2018","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0805","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/ni.2745","article-title":"Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells","volume":"14","author":"Skon","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0810","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/eji.201746928","article-title":"IL-2 is required for the generation of viral-specific CD4+ Th1 tissue-resident memory cells and B cells are essential for maintenance in the lung","volume":"48","author":"Hondowicz","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0815","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature04606","article-title":"CD69 acts downstream of interferon-\u03b1\/\u03b2 to inhibit S1P1 and lymphocyte egress from lymphoid organs","volume":"440","author":"Shiow","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0820","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1084\/jem.20141518","article-title":"ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis","volume":"212","author":"Moguche","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0825","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/ni.3589","article-title":"Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells","volume":"17","author":"Hombrink","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0830","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/mi.2014.87","article-title":"A major population of mucosal memory CD4+ T cells, coexpressing IL-18R\u03b1 and DR3, display innate lymphocyte functionality","volume":"8","author":"Holmkvist","year":"2015","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0835","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1038\/s41598-018-29456-w","article-title":"Type I interferon potentiates IgA immunity to respiratory syncytial virus infection during infancy","volume":"8","author":"Hijano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.003_bb0840","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0845","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009427","article-title":"Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model","volume":"17","author":"Bessi\u00e8re","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2023.01.003_bb0855","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.molmed.2023.01.003_bb0860","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2023.01.003_bb0865","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2018.07.034","article-title":"Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-\u03baB signaling after nuclear DNA damage","volume":"71","author":"Dunphy","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2023.01.003_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102801","article-title":"COVID-19 as a STING disorder with delayed over-secretion of interferon-beta","volume":"56","author":"Berthelot","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.molmed.2023.01.003_bb0875","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s42003-021-02983-5","article-title":"SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-\u03baB","volume":"5","author":"Neufeldt","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0880","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41577-020-00429-3","article-title":"The type I interferon response in COVID-19: implications for treatment","volume":"20","author":"Lee","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2023.01.003_bb0885","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature11522","article-title":"A vaccine strategy that protects against genital herpes by establishing local memory T cells","volume":"491","author":"Shin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.003_bb0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080559","article-title":"A \u201cprime-pull\u201d vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice","volume":"8","author":"Tregoning","year":"2013","journal-title":"PLoS One"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:27:29Z","timestamp":1761463649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491423000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":178,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1471491423000175"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2023.01.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}